Our data allowed us to identify the KCTD1 protein as a potential new biomarker of T-ALL, raising interest for future clinical investigations and validating its role not only as a diagnostic marker, but also as a new potential therapeutic target. The gene discussed is KCTD1; the disease is acute lymphoblastic leukemia.